Last reviewed · How we verify
NT 201
NT 201 is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to temporarily paralyze muscles.
NT 201 is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to temporarily paralyze muscles. Used for Temporary improvement of moderate to severe glabellar lines (frown lines) in adults, Temporary improvement of moderate to severe lateral canthal lines (crow's feet) in adults, Temporary improvement of moderate to severe forehead lines in adults.
At a glance
| Generic name | NT 201 |
|---|---|
| Also known as | IncobotulinumtoxinA, Xeomin/Bocouture, Xeomin Cosmetic, Xeomeen, Incobotulinumtoxin A |
| Sponsor | Merz Aesthetics GmbH |
| Drug class | Botulinum toxin type A |
| Target | SNARE complex (acetylcholine release machinery) |
| Modality | Small molecule |
| Therapeutic area | Aesthetics/Dermatology |
| Phase | FDA-approved |
Mechanism of action
NT 201 works by cleaving SNARE proteins required for acetylcholine vesicle fusion and release at motor nerve terminals. This results in temporary muscle relaxation and reduction of dynamic wrinkles and facial lines. The effect is reversible and typically lasts 3-4 months before neuromuscular function gradually recovers.
Approved indications
- Temporary improvement of moderate to severe glabellar lines (frown lines between eyebrows)
- Temporary improvement of forehead lines and crow's feet
Common side effects
- Headache
- Injection site pain or bruising
- Eyelid ptosis
- Brow ptosis
- Facial asymmetry
Key clinical trials
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction (PHASE2)
- Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine (PHASE3)
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine (PHASE3)
- Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury (PHASE3)
- IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia (PHASE3)
- Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |